EA200000012A1 - Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент - Google Patents

Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент

Info

Publication number
EA200000012A1
EA200000012A1 EA200000012A EA200000012A EA200000012A1 EA 200000012 A1 EA200000012 A1 EA 200000012A1 EA 200000012 A EA200000012 A EA 200000012A EA 200000012 A EA200000012 A EA 200000012A EA 200000012 A1 EA200000012 A1 EA 200000012A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
atorvastatin
subjects
combination therapy
antihypertensive agent
Prior art date
Application number
EA200000012A
Other languages
English (en)
Inventor
Роберт Эндрю Доналд Скотт
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200000012A1 publication Critical patent/EA200000012A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Это изобретение относится к фармацевтическим комбинациям аторвастатина или его фармацевтически приемлемой соли и антигипертензивных агентов, наборам, содержащим такие комбинации, и способам применения таких комбинаций для лечения субъектов, которые страдают стенокардией, атеросклерозом, сочетанием гипертензии и гиперлипидемии, и для лечения субъектов, которые имеют симптомы риска нарушения сердечной деятельности, в том числе людей. Это изобретение также относится к аддитивным и синергическим комбинациям аторвастатина или его фармацевтически приемлемой соли и антигипертензивных агентов, которые полезны при лечении субъектов, страдающих стенокардией, атеросклерозом, сочетанием гипертензии и гиперлипидемии, и субъектов, имеющих симптомы риска нарушения сердечной деятельности, в том числе людей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000012A 1997-08-29 1998-08-11 Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент EA200000012A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29
PCT/IB1998/001230 WO1999011260A1 (en) 1997-08-29 1998-08-11 Combination therapy comprising atorvastatin and an antihypertensive agent

Publications (1)

Publication Number Publication Date
EA200000012A1 true EA200000012A1 (ru) 2000-08-28

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000012A EA200000012A1 (ru) 1997-08-29 1998-08-11 Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент

Country Status (41)

Country Link
US (2) US20020099046A1 (ru)
EP (1) EP1009400B1 (ru)
JP (2) JP2001514223A (ru)
KR (3) KR20030015394A (ru)
CN (3) CN1268053A (ru)
AP (1) AP1191A (ru)
AR (1) AR016399A1 (ru)
AT (1) ATE285767T1 (ru)
AU (1) AU740424B2 (ru)
BG (1) BG64724B1 (ru)
BR (1) BR9811556A (ru)
CA (1) CA2296723A1 (ru)
CO (1) CO4970724A1 (ru)
DE (1) DE69828413T2 (ru)
DZ (1) DZ2595A1 (ru)
EA (1) EA200000012A1 (ru)
EG (1) EG24678A (ru)
ES (1) ES2234134T3 (ru)
GT (1) GT199800126A (ru)
HR (1) HRP980474A2 (ru)
HU (1) HUP0004318A3 (ru)
ID (1) ID24118A (ru)
IL (2) IL133962A0 (ru)
IS (1) IS5341A (ru)
MA (1) MA26536A1 (ru)
MY (1) MY121008A (ru)
NO (1) NO323987B1 (ru)
NZ (2) NZ530630A (ru)
OA (1) OA11291A (ru)
PA (1) PA8457901A1 (ru)
PE (1) PE107099A1 (ru)
PL (1) PL339091A1 (ru)
PT (1) PT1009400E (ru)
SA (1) SA98190603B1 (ru)
SK (1) SK1432000A3 (ru)
TN (1) TNSN98155A1 (ru)
TR (1) TR200000563T2 (ru)
UY (1) UY25155A1 (ru)
WO (1) WO1999011260A1 (ru)
YU (1) YU2000A (ru)
ZA (1) ZA987839B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000500B2 (en) 2014-10-23 2021-05-11 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
US11826471B2 (en) 2017-03-01 2023-11-28 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
AU1591699A (en) * 1998-03-17 1999-10-11 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
AU2001289672B2 (en) 2000-07-19 2005-12-08 Novartis Ag Valsartan salts
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
DE60220522T2 (de) * 2001-07-19 2007-09-27 Pharmacia Corp. Kombination von einem aldosterone rezeptor antagonisten und einem hmg coa reduktase hemmer
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE395936T1 (de) * 2002-06-20 2008-06-15 Univ Alberta Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
WO2004002472A1 (en) * 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
JP2005533823A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド リン酸カルベジロール塩および／またはその溶媒和物、対応する組成物、および／または治療方法
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
EP1734958A1 (en) * 2004-04-06 2006-12-27 Merck & Co., Inc. Methods for the treatment of hypertension
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20080070926A1 (en) * 2005-02-17 2008-03-20 Roberto Fogari Therapeutic Combinations of Manidi Pine and a Statin
CN101415425B (zh) 2006-03-29 2014-11-26 兴和株式会社 甘油三酯降低剂和高胰岛素血症改善剂
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
CN105163734A (zh) * 2013-03-12 2015-12-16 株式会社Lg生命科学 包含缬沙坦及罗舒伐他汀钙的复合制剂及其制造方法
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
KR20170003459A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
EP3463322A4 (en) * 2016-06-02 2019-11-20 Ana Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERCALCIURY AND NEPHRITICAL CALCULATION
JP2020506180A (ja) 2017-01-25 2020-02-27 ザ ジョージ インスティテュート フォー グローバル ヘルス 高血圧症の処置のための組成物
US20200030296A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
DE69636783T2 (de) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000500B2 (en) 2014-10-23 2021-05-11 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
US11426377B2 (en) 2014-10-23 2022-08-30 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
US11826337B2 (en) 2014-10-23 2023-11-28 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
US11826471B2 (en) 2017-03-01 2023-11-28 Arena Pharmaceuticals, Inc. Compositions comprising PGI2-receptor agonists and processes for the preparation thereof

Also Published As

Publication number Publication date
IL133962A (en) 2006-07-05
IL133962A0 (en) 2001-04-30
BG104075A (en) 2000-09-29
GT199800126A (es) 2000-01-29
EG24678A (en) 2010-04-27
TR200000563T2 (tr) 2000-07-21
MA26536A1 (fr) 2004-12-20
AP9801332A0 (en) 1998-09-30
US20030199492A1 (en) 2003-10-23
ZA987839B (en) 2000-02-28
UY25155A1 (es) 2000-12-29
OA11291A (en) 2003-08-25
JP2005041875A (ja) 2005-02-17
AP1191A (en) 2003-07-19
EP1009400A1 (en) 2000-06-21
US20020099046A1 (en) 2002-07-25
CN1268053A (zh) 2000-09-27
HRP980474A2 (en) 1999-06-30
ES2234134T3 (es) 2005-06-16
NO20000996L (no) 2000-04-27
MY121008A (en) 2005-12-30
NZ502280A (en) 2002-11-26
BG64724B1 (bg) 2006-01-31
DE69828413T2 (de) 2005-12-08
AR016399A1 (es) 2001-07-04
IS5341A (is) 2000-01-14
SA98190603B1 (ar) 2006-07-04
YU2000A (sh) 2002-12-10
EP1009400B1 (en) 2004-12-29
ATE285767T1 (de) 2005-01-15
CN1473567A (zh) 2004-02-11
KR20010022477A (ko) 2001-03-15
KR20030015394A (ko) 2003-02-20
CA2296723A1 (en) 1999-03-11
KR20040106591A (ko) 2004-12-17
CO4970724A1 (es) 2000-11-07
PL339091A1 (en) 2000-12-04
SK1432000A3 (en) 2000-12-11
AU8458998A (en) 1999-03-22
PT1009400E (pt) 2005-02-28
BR9811556A (pt) 2000-08-22
AU740424B2 (en) 2001-11-01
PE107099A1 (es) 1999-11-06
ID24118A (id) 2000-07-06
NO323987B1 (no) 2007-07-30
JP2001514223A (ja) 2001-09-11
HUP0004318A3 (en) 2002-10-28
HUP0004318A2 (hu) 2001-05-28
DE69828413D1 (de) 2005-02-03
PA8457901A1 (es) 2000-05-24
CN1473566A (zh) 2004-02-11
NZ530630A (en) 2005-05-27
TNSN98155A1 (fr) 2005-03-15
WO1999011260A1 (en) 1999-03-11
DZ2595A1 (fr) 2003-02-22
NO20000996D0 (no) 2000-02-28

Similar Documents

Publication Publication Date Title
EA200000012A1 (ru) Комбинационная терапия, включающая в себя аторвастатин и антигипертензивный агент
EA200000164A1 (ru) Терапевтические комбинации, включающие в себя амлодипин и аторвастатин
EA200000013A1 (ru) Комбинационная терапия, включающая в себя амлодипин и статиновое соединение
DK0891331T3 (da) N-(2-Oxoacetyl- eller sulfonyl)pyrrolidin/piperidin-2-carboxylsyrederivater med forbedret multi-lægemiddelresistensaktivitet
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
IL132853A0 (en) Combination therapy for modulating the human sexual response
DE69821524D1 (de) Verwendung von vitis vinifera extrakten phospholipid komplexen als antiatherosclerotische mitteln
WO1998042650A3 (en) Leukotriene antagonists useful for treating cystic fibrosis
ECSP982645A (es) Terapia de combinacion
CY1106922T1 (el) Ενωσεις ισοκινολινυλ αροϋλ πυρρολης για την αγωγη των διαταραχων κεντρικου νευρικου συστηματος
ECSP982646A (es) Combinaciones terapeuticas